Oncolytics Biotech’s (ONCY) “Hold” Rating Reiterated at Jones Trading

Jones Trading reissued their hold rating on shares of Oncolytics Biotech (NASDAQ:ONCY) in a research note released on Friday morning,Benzinga reports.

Several other equities analysts have also commented on ONCY. Maxim Group decreased their price target on Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Oncolytics Biotech in a report on Monday, March 10th. Finally, Royal Bank of Canada decreased their target price on shares of Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a research report on Monday, March 10th. One research analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $4.33.

Oncolytics Biotech Price Performance

Shares of ONCY stock opened at $0.47 on Friday. The company has a market capitalization of $40.41 million, a PE ratio of -1.73 and a beta of 1.00. The firm’s 50-day moving average is $0.56 and its two-hundred day moving average is $0.75. Oncolytics Biotech has a 12 month low of $0.45 and a 12 month high of $1.53.

Oncolytics Biotech (NASDAQ:ONCY) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. Sell-side analysts forecast that Oncolytics Biotech will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Oncolytics Biotech

Institutional investors have recently bought and sold shares of the company. Virtu Financial LLC purchased a new position in shares of Oncolytics Biotech in the fourth quarter valued at approximately $90,000. National Bank of Canada FI boosted its position in Oncolytics Biotech by 199.6% in the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock valued at $60,000 after buying an additional 42,955 shares during the period. Vantage Point Financial LLC purchased a new position in Oncolytics Biotech in the 4th quarter valued at approximately $27,000. Finally, Geode Capital Management LLC grew its stake in shares of Oncolytics Biotech by 59.6% in the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after acquiring an additional 24,997 shares in the last quarter. 6.82% of the stock is owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.